Group 1 - The company held its 12th meeting of the third board of directors on September 19, 2025, with all seven directors present, and the meeting was deemed legal and effective [2][3][4] - The board approved the draft of the 2025 Restricted Stock Incentive Plan to attract and retain talented management and align interests among shareholders, the company, and key personnel [3][5][6] - The board also approved the management measures for the implementation of the 2025 Restricted Stock Incentive Plan to ensure its smooth operation and performance [5][6][7] Group 2 - The company proposed to use up to RMB 680 million of idle raised funds and up to RMB 620 million of its own funds for cash management, aiming to improve fund utilization efficiency without affecting normal operations [14][21][24] - The cash management will involve purchasing low-risk financial products, ensuring that the funds remain secure and liquid [26][28][30] - The board's decision on cash management is subject to approval at the upcoming second extraordinary general meeting of shareholders on October 20, 2025 [16][20][45] Group 3 - The company will hold its second extraordinary general meeting of shareholders on October 20, 2025, with provisions for both on-site and online voting [16][46][49] - The meeting will require a two-thirds majority vote for special resolutions related to the restricted stock incentive plan [49] - Shareholders must register for the meeting and can participate either in person or through online voting [48][50][51]
辽宁何氏眼科医院集团股份有限公司第三届董事会第十二次会议决议公告